The Chemical Biology Core assists researchers in identifying and optimizing chemical probes and new lead compounds that can aid drug discovery &development and ultimately provide therapeutic benefit to cancer patients. The core is comprised of four functional units: ? Experimental High Throughput Screening Unit (Experimental HTS lab) ? Virtual HTS and Molecular Modeling Unit (Virtual HTS lab) ? Chemical Intermediates and Library Synthesis Unit (Chemistry lab) ? Protein Crystallography Unit (Protein Crystallography, being added recently) Over the last five years, the core developed the Protein Crystallography Unit, which provides all services needed from cloning the DNA sequence to determining the crystal structure. The addition of the Protein Crystallography Unit led to the renaming of the HTS &Chemistry core to """"""""Chemical Biology Core"""""""". In 2007, Moffitt recruited Ernst Schonbrunn, PhD, to lead this unit and serve as Co-Scientific Director with Dr. Guida. Under their joint leadership and due to the substantially increased demand for x-ray usage, additional equipment was acquired, including an upgraded X-ray generator in 2009. The Core requests CCSG Support of $363,941, which is 42% of its operational budget. Usage has grown to 22 active projects and Over 90% of usage is by Moffitt members and peer-reviewed.
The Chemical Biology core provides four fundamental services to enhance the research for Moffitt investigators that significantly impact the drug discovery process. Core has been highly successful in stimulating Cancer Center investigators grant applications in chemical biology approaches to cancer studies. In addition, the shared resource provides access to many kinds of equipment that are too expensive for the average laboratory to own individually.
|Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612|
|Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53|
|Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303|
|Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73|
|Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :|
|Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880|
|Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029|
|Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :|
|Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96|
Showing the most recent 10 out of 974 publications